NURS_602: APEA Hollier FNP Certification Practice
Question Bank & Predictor Exam Elaborations
Course Code: NURS_602
Course Name: Family Nurse Practitioner (FNP) Certification Review
Topic: Advanced Clinical Pathophysiology, Pharmacotherapeutics, and Evidence-
Based Diagnostic Integration
Academic Year: 2026/2027
1. A 45-year-old female presents with a 3-month history of symmetric joint
stiffness in her hands, wrists, and feet, which is most severe in the morning
and lasts for more than 1 hour. On physical examination, the nurse
practitioner notes soft tissue swelling and tenderness across the
metacarpophalangeal (MCP) joints. Laboratory analysis reveals a positive
, rheumatoid factor and highly elevated anti-cyclic citrullinated peptide (anti-
CCP) antibodies. Which pharmacological agent represents the correct
answer as the first-line disease-modifying antirheumatic drug (DMARD) of
choice?
A. Oral prednisone taper over 4 weeks
B. Hydroxychloroquine monotherapy
C. Methotrexate initiated with concurrent folic acid supplementation
D. Scheduled high-dose naproxen daily
CORRECT ANSWER: C. Methotrexate initiated with concurrent folic acid
supplementation
RATIONALE: The client's clinical presentation and serological markers
(positive RF and high anti-CCP) confirm a diagnosis of rheumatoid arthritis
(RA). Guidelines from the American College of Rheumatology (ACR) dictate that
methotrexate is the first-line anchor disease-modifying antirheumatic drug
(DMARD) for moderate-to-severe RA due to its robust efficacy in arresting joint
destruction and slowing radiographic progression. Folic acid is co-administered to
reduce adverse toxicities like mucosal ulcerations and hepatic irritation.
Corticosteroids and NSAIDs are utilized only as short-term bridge therapies for
acute symptom suppression but do not alter the underlying disease path.
Hydroxychloroquine is typically reserved for mild or seronegative disease variants.
2. A 67-year-old male with a history of severe chronic obstructive
pulmonary disease (COPD) presents to the clinic for a routine follow-up.
His spirometry results demonstrate a post-bronchodilator FEV1/FVC ratio of
under 0.70, and an FEV1 of 45% of predicted value, classifying him as
GOLD Group E due to multiple hospitalizations over the past year. Which
maintenance pharmacological regimen represents the correct answer to
maximize bronchodilation and reduce future exacerbations?
A. Scheduled short-acting albuterol inhaler used every 4 hours as a
standalone controller.
B. Inhaled corticosteroid (ICS) monotherapy.
C. A triple therapy combination consisting of a Long-Acting Muscarinic
Antagonist (LAMA), a Long-Acting Beta2-Agonist (LABA), and an
Inhaled Corticosteroid (ICS).
D. Oral theophylline titrated to narrow therapeutic serum levels.
, CORRECT ANSWER: C. A triple therapy combination consisting of a
Long-Acting Muscarinic Antagonist (LAMA), a Long-Acting Beta2-Agonist
(LABA), and an Inhaled Corticosteroid (ICS).
RATIONALE: According to the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) guidelines, clients with severe airflow limitation and a history of
recurrent exacerbations fall into GOLD Group E. For these individuals, triple
inhalation therapy (LAMA + LABA + ICS) is the first-line recommendation.
This regimen maximizes distinct bronchodilator pathways while utilizing the anti-
inflammatory action of the ICS to substantially drop subsequent hospitalization
events. Short-acting monotherapy is for rescue use only, not chronic maintenance.
ICS monotherapy is strictly contraindicated in COPD due to lack of efficacy and
increased pneumonia risks. Theophylline is an outdated drug with a narrow
therapeutic window and high toxicity profile in geriatric cohorts.
3. A 29-year-old female presents for a routine evaluation of her type 2
diabetes mellitus. Her current hemoglobin A1c is 8.4% despite optimal,
maximum-tolerated lifestyle modifications and oral metformin therapy. The
client's past medical history is significant for a body mass index (BMI) of
34.2 kg/m² and a confirmed history of atherosclerotic cardiovascular
disease (ASCVD). Which medication class should the nurse practitioner
select next as the most appropriate clinical choice?
A. Sulfonylureas such as glimepiride to stimulate insulin release.
B. Thiazolidinediones such as pioglitazone to enhance peripheral sensitivity.
C. Glucagon-like peptide-1 (GLP-1) receptor agonists with proven
cardiovascular benefits, such as semaglutide.
D. Bedtime basal insulin analogs to suppress nocturnal gluconeogenesis.
CORRECT ANSWER: C. Glucagon-like peptide-1 (GLP-1) receptor
agonists with proven cardiovascular benefits, such as semaglutide.
RATIONALE: Joint guidelines from the American Diabetes Association
(ADA) specify that for clients with type 2 diabetes who have established
atherosclerotic cardiovascular disease (ASCVD) or high cardiovascular risk, the
addition of a GLP-1 receptor agonist or an SGLT2 inhibitor with demonstrated
cardiovascular benefit is indicated, independent of the baseline HbA1c. These
agents provide independent cardiovascular protection, substantial weight
reduction, and optimal glycemic control. Sulfonylureas carry high hypoglycemia
risks. Thiazolidinediones can cause fluid retention and increase heart failure
, events. Basal insulin is a late-stage option and does not provide ASCVD-specific
risk reduction.
4. A 72-year-old female presents to the clinic with complaints of progressive,
asymmetric joint pain localized to her right knee and left hip. She states the
pain is worse at the end of the day after physical activity and improves
significantly with rest. Physical examination reveals crepitus over the right
patella and the presence of Heberden's nodes on the distal interphalangeal
(DIP) joints. What is the correct answer for the diagnosis?
A. Acute gouty arthritis
B. Rheumatoid arthritis
C. Osteoarthritis
D. Systemic lupus erythematosus
CORRECT ANSWER: C. Osteoarthritis
RATIONALE: Osteoarthritis (OA) is a degenerative, non-inflammatory joint
disease characterized by asymmetric joint involvement, pain that worsens with
activity and improves with rest, crepitus, and bony enlargements known as
Heberden's nodes (at the DIP joints) and Bouchard's nodes (at the PIP joints).
Rheumatoid arthritis is a symmetric, inflammatory autoimmune disorder
presenting with soft, warm swelling that exhibits morning stiffness lasting more
than an hour and improves with activity. Gout presents as acute, sudden
monoarticular inflammatory attacks, typically at the first metatarsophalangeal
joint.
5. A 74-year-old male presents for a routine wellness examination. On
cardiovascular auscultation, the nurse practitioner notes a crescendo-
decrescendo systolic murmur at the right upper sternal border that radiates
directly into the carotid arteries. The client reports mild exertional dyspnea.
Which of the following conditions is the correct diagnosis?
A. Mitral valve regurgitation
B. Aortic valve stenosis
C. Mitral valve prolapse
D. Tricuspid regurgitation
CORRECT ANSWER: B. Aortic valve stenosis
RATIONALE: Aortic stenosis is the most common valvular disease in elderly
adults, typically driven by progressive age-related calcification. The classic
Question Bank & Predictor Exam Elaborations
Course Code: NURS_602
Course Name: Family Nurse Practitioner (FNP) Certification Review
Topic: Advanced Clinical Pathophysiology, Pharmacotherapeutics, and Evidence-
Based Diagnostic Integration
Academic Year: 2026/2027
1. A 45-year-old female presents with a 3-month history of symmetric joint
stiffness in her hands, wrists, and feet, which is most severe in the morning
and lasts for more than 1 hour. On physical examination, the nurse
practitioner notes soft tissue swelling and tenderness across the
metacarpophalangeal (MCP) joints. Laboratory analysis reveals a positive
, rheumatoid factor and highly elevated anti-cyclic citrullinated peptide (anti-
CCP) antibodies. Which pharmacological agent represents the correct
answer as the first-line disease-modifying antirheumatic drug (DMARD) of
choice?
A. Oral prednisone taper over 4 weeks
B. Hydroxychloroquine monotherapy
C. Methotrexate initiated with concurrent folic acid supplementation
D. Scheduled high-dose naproxen daily
CORRECT ANSWER: C. Methotrexate initiated with concurrent folic acid
supplementation
RATIONALE: The client's clinical presentation and serological markers
(positive RF and high anti-CCP) confirm a diagnosis of rheumatoid arthritis
(RA). Guidelines from the American College of Rheumatology (ACR) dictate that
methotrexate is the first-line anchor disease-modifying antirheumatic drug
(DMARD) for moderate-to-severe RA due to its robust efficacy in arresting joint
destruction and slowing radiographic progression. Folic acid is co-administered to
reduce adverse toxicities like mucosal ulcerations and hepatic irritation.
Corticosteroids and NSAIDs are utilized only as short-term bridge therapies for
acute symptom suppression but do not alter the underlying disease path.
Hydroxychloroquine is typically reserved for mild or seronegative disease variants.
2. A 67-year-old male with a history of severe chronic obstructive
pulmonary disease (COPD) presents to the clinic for a routine follow-up.
His spirometry results demonstrate a post-bronchodilator FEV1/FVC ratio of
under 0.70, and an FEV1 of 45% of predicted value, classifying him as
GOLD Group E due to multiple hospitalizations over the past year. Which
maintenance pharmacological regimen represents the correct answer to
maximize bronchodilation and reduce future exacerbations?
A. Scheduled short-acting albuterol inhaler used every 4 hours as a
standalone controller.
B. Inhaled corticosteroid (ICS) monotherapy.
C. A triple therapy combination consisting of a Long-Acting Muscarinic
Antagonist (LAMA), a Long-Acting Beta2-Agonist (LABA), and an
Inhaled Corticosteroid (ICS).
D. Oral theophylline titrated to narrow therapeutic serum levels.
, CORRECT ANSWER: C. A triple therapy combination consisting of a
Long-Acting Muscarinic Antagonist (LAMA), a Long-Acting Beta2-Agonist
(LABA), and an Inhaled Corticosteroid (ICS).
RATIONALE: According to the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) guidelines, clients with severe airflow limitation and a history of
recurrent exacerbations fall into GOLD Group E. For these individuals, triple
inhalation therapy (LAMA + LABA + ICS) is the first-line recommendation.
This regimen maximizes distinct bronchodilator pathways while utilizing the anti-
inflammatory action of the ICS to substantially drop subsequent hospitalization
events. Short-acting monotherapy is for rescue use only, not chronic maintenance.
ICS monotherapy is strictly contraindicated in COPD due to lack of efficacy and
increased pneumonia risks. Theophylline is an outdated drug with a narrow
therapeutic window and high toxicity profile in geriatric cohorts.
3. A 29-year-old female presents for a routine evaluation of her type 2
diabetes mellitus. Her current hemoglobin A1c is 8.4% despite optimal,
maximum-tolerated lifestyle modifications and oral metformin therapy. The
client's past medical history is significant for a body mass index (BMI) of
34.2 kg/m² and a confirmed history of atherosclerotic cardiovascular
disease (ASCVD). Which medication class should the nurse practitioner
select next as the most appropriate clinical choice?
A. Sulfonylureas such as glimepiride to stimulate insulin release.
B. Thiazolidinediones such as pioglitazone to enhance peripheral sensitivity.
C. Glucagon-like peptide-1 (GLP-1) receptor agonists with proven
cardiovascular benefits, such as semaglutide.
D. Bedtime basal insulin analogs to suppress nocturnal gluconeogenesis.
CORRECT ANSWER: C. Glucagon-like peptide-1 (GLP-1) receptor
agonists with proven cardiovascular benefits, such as semaglutide.
RATIONALE: Joint guidelines from the American Diabetes Association
(ADA) specify that for clients with type 2 diabetes who have established
atherosclerotic cardiovascular disease (ASCVD) or high cardiovascular risk, the
addition of a GLP-1 receptor agonist or an SGLT2 inhibitor with demonstrated
cardiovascular benefit is indicated, independent of the baseline HbA1c. These
agents provide independent cardiovascular protection, substantial weight
reduction, and optimal glycemic control. Sulfonylureas carry high hypoglycemia
risks. Thiazolidinediones can cause fluid retention and increase heart failure
, events. Basal insulin is a late-stage option and does not provide ASCVD-specific
risk reduction.
4. A 72-year-old female presents to the clinic with complaints of progressive,
asymmetric joint pain localized to her right knee and left hip. She states the
pain is worse at the end of the day after physical activity and improves
significantly with rest. Physical examination reveals crepitus over the right
patella and the presence of Heberden's nodes on the distal interphalangeal
(DIP) joints. What is the correct answer for the diagnosis?
A. Acute gouty arthritis
B. Rheumatoid arthritis
C. Osteoarthritis
D. Systemic lupus erythematosus
CORRECT ANSWER: C. Osteoarthritis
RATIONALE: Osteoarthritis (OA) is a degenerative, non-inflammatory joint
disease characterized by asymmetric joint involvement, pain that worsens with
activity and improves with rest, crepitus, and bony enlargements known as
Heberden's nodes (at the DIP joints) and Bouchard's nodes (at the PIP joints).
Rheumatoid arthritis is a symmetric, inflammatory autoimmune disorder
presenting with soft, warm swelling that exhibits morning stiffness lasting more
than an hour and improves with activity. Gout presents as acute, sudden
monoarticular inflammatory attacks, typically at the first metatarsophalangeal
joint.
5. A 74-year-old male presents for a routine wellness examination. On
cardiovascular auscultation, the nurse practitioner notes a crescendo-
decrescendo systolic murmur at the right upper sternal border that radiates
directly into the carotid arteries. The client reports mild exertional dyspnea.
Which of the following conditions is the correct diagnosis?
A. Mitral valve regurgitation
B. Aortic valve stenosis
C. Mitral valve prolapse
D. Tricuspid regurgitation
CORRECT ANSWER: B. Aortic valve stenosis
RATIONALE: Aortic stenosis is the most common valvular disease in elderly
adults, typically driven by progressive age-related calcification. The classic
